恩华药业：右酮洛芬氨丁三醇注射液获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of a new chemical drug, Ketorolac Tromethamine Injection, which is a non-steroidal anti-inflammatory analgesic used for acute moderate to severe postoperative pain in adults who are unsuitable for oral administration [1] Group 1 - The drug Ketorolac Tromethamine Injection acts as an inhibitor of COX-1 and COX-2 enzymes [1] - It is intended to be used as an adjunct to opioid analgesics [1] - The approval signifies a potential expansion in the company's product offerings in the pain management segment [1]